Characteristics of fatalities
| IRD | PsA | RA | RA | RA | PsA | RA |
|---|---|---|---|---|---|---|
| Age (years) | 64 | 70 | 80 | 80 | 59 | 72 |
| Gender | M | M | F | F | M | F |
| BMI (kg/m2) | 40.6 | 27.8 | 28.7 | 23.9 | 27.8 | 26.6 |
| Antirheumatic therapy | GC | SSZ | GC, MTX | GC, MTX, RTX | GC, SSZ | GC, MTX, ABC |
| Comorbidities | CVD COPD | AHT | CVD AHT COPD | AHT Osteoporosis | CVD AHT Cancer Other | AHT COPD |
| Disease duration (COVID-19) | 6 days | 8 days | 14 days | 21 days | 18 days | 20 days |
| Symptoms (COVID-19) | Fever Dyspnea | Fever Cough | Fever Dyspnea Chest pain | Fever Cough Dyspnea Vertigo Fatigue | Fever Dyspnea Cough | Dyspnea |
| Invasive ventilation | Yes | Yes | Yes | Yes | Yes | Yes |
| Interruption DMARD | Yes | Yes | Yes, MTX | Yes, MTX and RTX | No | Yes, ABC and MTX |
ABC, abatacept; AHT, arterial hypertension; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular diseases; DMARD, disease-modifying antirheumatic drugs; F, female; GC, glucocorticosteroids; IRD, inflammatory rheumatic diseases; M, male; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RTX, rituximab; SSZ, sulphasalazine.